A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin and Radiotherapy in Patients With Advanced Head and Neck Carcinoma (Unresectable and Inoperable).

Trial Profile

A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin and Radiotherapy in Patients With Advanced Head and Neck Carcinoma (Unresectable and Inoperable).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2009

At a glance

  • Drugs Cisplatin; Gefitinib
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top